safety findings for axi-cel in patients with dlbcl
Published 5 years ago • 59 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:34
zuma-1 update: safety data of axi-cel in patients with r/r dlbcl
-
1:17
real-world data for axi-cel in broader dlbcl population
-
0:34
rationale for genetic testing in patients with dlbcl
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
8:54
safety and efficacy of oral agents in r/r dlbcl
-
1:09
dr. neelapu discusses efficacy of axi-cel in large b-cell lymphoma
-
1:22
dr. jacobson on the safety profile of axi-cel in relapsed/refractory indolent lymphoma
-
4:05
selecting therapy for relapsed-refractory dlbcl
-
1:39
expert discusses data for flyer trial in patients with dlbcl
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
22:26
key novel agents for relapsed diffuse large b-cell lymphoma
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
1:19
toxicity profile of car t-cell therapy appears safe in follicular and marginal zone lymphomas
-
1:36
real-world comparison of axi-cel and tisa-cel in r/r dlbcl
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
3:02
real-world efficacy & safety data: car-t in dlbcl
-
3:15
treatment limitations in dlbcl
-
1:45
matched comparison of tisa-cel and axi-cel in r/r dlbcl